Journals / Türkiye Parazitoloji Dergisi / 2013 / Cilt: 37 - Sayı: 3

Toxoplasma uveitis in a Patient with Ankylosing Spondylitis

Ankilozan Spondilitli olguda Toxoplasma üveiti

Pages
216–218
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

A delay in diagnosis and treatment may result in failure in obtaining the desired outcome from medical treatment and a shift to surgical treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:In this paper, a posterior uveitis case was reported in a patient who was being followed and under treatment for Ankylosing Spondylitis.
📊
Key Findings & Data:Toxoplasma antibodies were investigated and anti-toxoplasma IgG was positive.
💡
Conclusion & Impact:A delay in diagnosis and treatment may result in failure in obtaining the desired outcome from medical treatment and a shift to surgical treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

In this paper, a posterior uveitis case was reported in a patient who was being followed and under treatment for Ankylosing Spondylitis. Toxoplasma antibodies were investigated and anti-toxoplasma IgG was positive. Systematic treatment (Sulfamethoxazole/Trimethoprim and Clindamycin) was started. Despite medical treatment, reduction in visual acuity and development of dense membranous condensation in vitreous occurred. Surgical vitrectomy was performed. When posterior uveitis develops in patients who undergo immunosuppressive treatment, toxoplasma is among the first infectious agents that we should consider. A delay in diagnosis and treatment may result in failure in obtaining the desired outcome from medical treatment and a shift to surgical treatment.

Özet

Bu bildiride Ankilozan Spondilit tanısıyla izlenen ve immun supresif tedavi uygulanan bir hastada gelişen posterior üveit tablosu ele alınmıştır. Hastada anti-Toxoplasma antikorları araştırılmıştır, anti-Toxoplasma IgG pozitif olarak saptanmıştır. Olguya sistemik tedavi (Trimetoprim Sulfametaksazol ve Klindamisin) başlanmıştır. Takiplerde görme keskinliğinde azalma ve vitreus içinde yoğun membranöz kondansasyon gelişmesi nedeniyle vitrektomi uygulanmıştır. İmmunsupresif tedavi uygulanan hastalarda posterior üveit geliştiğinde Toxoplasma gondii öncelikle düşünmemiz gereken enfeksiyon ajanlarından birisidir. Tanı ve tedavide gecikme medikal tedaviden istediğimiz yanıtı alamayıp cerrahi tedaviye geçmemize yol açabilir.

🔖

Cite This Article

DEVECİ, H., KOBAK, Ş. (2022). Toxoplasma uveitis in a Patient with Ankylosing Spondylitis. Türkiye Parazitoloji Dergisi, Cilt: 37 - Sayı: 3, 216–218. https://ajindex.com/articles/630318

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Ho-Yen DO. Joss AWL (eds). Clinical features. Human toxoplasmo- sis. Oxford University Press New York 1992; 3: 56-74
  2. Vasconcelos-Santos DV. Ocular manifestations of systemic disease toxoplasmosis. Curr Opin Ophthalmol. 2012; 23: 543-50 [CrossRef] 3. Türk M, Gürüz AY. Oküler toxoplasmosis tanısında nested polimeraz zincir reaksiyonunun yeri. T Parazitol Derg 2002; 26: 335-41
  3. Roberts F, McLeod R. Pathogenesis of toxoplasmic retinocohoroidi- tis. Parasitology Today. 1999; 15: 51-7. [CrossRef] 5. Bölük S, Ozyurt BC, Girginkardeşler N, Kilimcioğlu AA. Evaluation of serological results of patients with suspected Toxoplasmosis admit- ted to the medical parasitology laboratory of Celal Bayar University Hospital Turkiye Parazitol Derg 2012; 36: 137-41
  4. Holland GN. Ocular toxoplasmosis a global reassessment Part I epidemiology and course of disease. Am J Ophthalmol 2003; 136: 973-88. [CrossRef] 7. London NJ, Hovakimyan A, Cubillan LD, Siverio CD Jr, Cunningham ET Jr. Prevalence, clinical characteristics, and causes of vision loss in patients with ocular toxoplasmosis. Eur J Ophthalmol 2011; 21: 811-9. [CrossRef] 8. Park YH. Toxoplasma gondii in the peripheral blood of patients with ocular toxoplasmosis. Br J Ophthalmol 2012; 96: 766. [CrossRef] 9. Linssen A, Meenken C. Outcomes of HLA-B27 positive and HLA- B27 negative acute anterior uveitis. Am J Ophthalmol 1995; 120: 351-61
  5. Montoya JG, Remington JS. Toxoplasmic chorioretinitis in the setting of acute acquired toxoplasmosis. Clin Infect Dis 1996; 23: 277-82. [CrossRef] 11. Kanski JJ. Clinical Ophthalmology. Uveitis. Butterworth Heinemann Oxford 1994. p. 295-300
  6. Holliman RE, Stevens PJ, Duffy KT, Johnson JD. Serological investi- gation of ocular toxoplasmosis. Br J Ophthalmol 1991; 75: 353-5. [CrossRef] 13. Bodaghi B, Touitou V, Fardeau C, Paris L, LeHoang P. Toxoplasmosis new challenges for an old disease. Eye (Lond) 2012; 26: 241-4. [CrossRef] 14. Yolasığmaz A, Şakru N, Yazar S, Akısü Ç, Gürüz AY, Kuman HA et al. Investigation of anti-toxoplasma antibodies in residence of urban and rural aeras. Türkiye Parazitol Derg 2003; 27: 81-4
  7. Engstrom RE, Jr, Hollang GN, Nussenblatt RB, Jabs DA. Current practices in the management of ocular toxoplasmosis. Am J Ophthalmol 1991; 111: 601-10
  8. Kim SJ, Scott IU, Brown GC, Brown MM, Ho AC, Ip MS,et al. Interventions for toxoplasma retinochoroiditis a report by the American Academy of Ophthalmology. Ophthalmology 2013; 120: 371-8. [CrossRef]